MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Verastem Company Profile (NASDAQ:VSTM)

Consensus Ratings for Verastem (NASDAQ:VSTM) (?)
Ratings Breakdown: 5 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Hold (Score: 2.38)
Consensus Price Target: $3.00 (129.01% upside)

Analysts' Ratings History for Verastem (NASDAQ:VSTM)
Show:
DateFirmActionRatingPrice TargetActions
3/7/2016HC WainwrightReiterated RatingBuy$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/13/2016Cantor FitzgeraldUpgradeHold -> Buy$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2015OppenheimerReiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/29/2015Jefferies GroupLower Price Target$18.00 -> $2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/29/2015JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/29/2015Raymond JamesDowngradeStrong-Buy -> Outperform$12.00 -> $3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/28/2015MizuhoDowngradeBuy -> Neutral$21.00 -> $2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/28/2015Roth CapitalDowngradeBuy -> Neutral$23.00 -> $2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/16/2014Wells FargoInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/8/2014GuggenheimBoost Price TargetBuy$18.00 -> $21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/11/2014Deutsche BankReiterated RatingBuy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Verastem (NASDAQ:VSTM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/9/2016($0.30)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2016Q415($0.36)($0.32)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q2($0.45)($0.42)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q1($0.41)($0.46)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2015($0.54)($0.53)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014($0.51)($0.52)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014($0.43)($0.51)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/6/2014Q4($0.47)($0.45)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3($0.44)($0.47)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2013Q2 2013($0.41)($0.49)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.43)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Verastem (NASDAQ:VSTM)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.32)($0.32)($0.32)
Q2 20161($0.33)($0.33)($0.33)
Q3 20162($0.33)($0.27)($0.30)
Q4 20162($0.34)($0.33)($0.34)
(Data provided by Zacks Investment Research)
Dividend History for Verastem (NASDAQ:VSTM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Verastem (NASDAQ:VSTM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/29/2015Monica SinghGeneral CounselBuy1,000$6.95$6,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/29/2015Robert ForresterCEOBuy2,000$7.11$14,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Dan PatersonCOOBuy1,000$8.05$8,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2015Robert ForresterCEOBuy1,000$7.97$7,970.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/28/2015Christoph H WestphalChairmanBuy1,230,769$6.50$7,999,998.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/28/2015Timothy J BarberichDirectorBuy38,462$6.50$250,003.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2014Joanna HorobinInsiderBuy750$8.60$6,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2014S. Louise PhanstielDirectorBuy10,000$8.54$85,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/26/2014Stephen A SherwinDirectorBuy2,500$8.56$21,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/24/2014Paul A FriedmanDirectorBuy3,000$8.31$24,930.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2014Henri A TermeerDirectorBuy19,100$8.09$154,519.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2014Monica SinghGeneral CounselBuy1,000$8.09$8,090.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2014Christoph H WestphalChairmanBuy1,500$8.50$12,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2014Dan PatersonCOOBuy2,000$8.52$17,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2014Robert ForresterCEOBuy1,000$8.66$8,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2014Alison Frances LawtonDirectorBuy2,500$9.17$22,925.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014Michael KauffmanDirectorBuy3,000$9.10$27,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/30/2014Timothy J BarberichDirectorBuy1,000$9.90$9,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2014Richard AldrichDirectorBuy1,000$8.37$8,370.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2014Dan PatersonInsiderBuy1,000$7.47$7,470.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2014Christoph WestphalChairmanBuy2,000$7.56$15,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2014Robert ForresterCEOBuy1,000$7.62$7,620.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2013Christoph WestphalDirectorBuy1,000$9.60$9,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2013Richard AldrichDirectorBuy1,000$10.93$10,930.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/4/2013Richard AldrichDirectorBuy1,000$10.51$10,510.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/28/2013Richard AldrichDirectorBuy1,000$11.26$11,260.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2013Richard AldrichDirectorBuy1,000$12.57$12,570.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/14/2013Richard AldrichDirectorBuy1,000$10.56$10,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2013Richard AldrichDirectorBuy1,000$11.53$11,530.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2013Richard AldrichDirectorBuy1,000$12.55$12,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2013Richard AldrichDirectorBuy1,000$13.17$13,170.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Richard AldrichDirectorBuy1,000$13.81$13,810.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2013Richard AldrichDirectorBuy1,000$14.04$14,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Richard AldrichDirectorBuy1,000$14.07$14,070.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2013Richard AldrichDirectorBuy1,000$14.21$14,210.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2013Richard AldrichDirectorBuy1,000$13.45$13,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2013Richard AldrichDirectorBuy1,000$14.75$14,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/5/2013Richard AldrichDirectorBuy1,000$15.25$15,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/29/2013Richard AldrichDirectorBuy1,000$15.15$15,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/24/2013Richard AldrichDirectorBuy1,000$16.39$16,390.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2013Richard AldrichDirectorBuy1,000$17.19$17,190.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2013Richard AldrichDirectorBuy1,000$14.69$14,690.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Richard AldrichDirectorBuy1,000$14.11$14,110.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2013Robert ForresterCOOBuy1,000$11.39$11,390.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2013Henri A TermeerDirectorBuy5,823$9.74$56,716.02View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2013Lp Chp IIIMajor ShareholderBuy48,171$9.40$452,807.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2013S. Louise PhanstielDirectorBuy12,000$9.30$111,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/7/2013Christoph H WestphalCEOBuy1,000$9.06$9,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2013John K ClarkeDirectorBuy25,000$9.74$243,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2013John K ClarkeDirectorBuy10,000$9.66$96,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/17/2013John K ClarkeDirectorBuy5,631$9.50$53,494.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2012Lp Chp IIIMajor ShareholderBuy6,193$7.87$48,738.91View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Verastem (NASDAQ:VSTM)
DateHeadline
06/20/16 06:40 PMThis Weeks Broker Views For Verastem, Inc. (VSTM) - Fiscal Standard
06/14/16 03:19 PMVerastem Announces Changes to its Board of Directors - [at noodls] - BOSTON--(BUSINESS WIRE)--Jun. 14, 2016-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced several changes to the Company's Board of Directors. ...
06/11/16 10:06 AMVerastem Inc. (VSTM) Drops 5.63% on June 09 - Equities.com
06/10/16 07:36 PMVerastem, Inc. (NASDAQ:VSTM) Dropped-5.63%: Waters Corporation (NYSE:WAT), Kaman Corporation (NYSE:KAMN ... - KC Register
06/10/16 04:00 PMVerastem, Inc. :VSTM-US: Earnings Analysis: Q1, 2016 By the Numbers : June 10, 2016 -
06/02/16 10:30 AMVerastem, Inc. (NASDAQ:VSTM) Stock Update & Estimates - Stock Tick Tock - Verastem, Inc. (NASDAQ:VSTM) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Verastem, Inc. (NASDAQ:VSTM) to post earnings of $-0.31 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued around ...and more »
06/01/16 06:13 AMVerastem to Present at Upcoming Investor Conferences - [at noodls] - BOSTON--(BUSINESS WIRE)--Jun. 1, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the following upcoming ...
05/31/16 10:04 AMSeaDrill (NYSE:SDRL) went up 3.81%: ChemoCentryx (NASDAQ:CCXI), Verastem (NASDAQ:VSTM), Sophiris Bio, Inc ... - KC Register - SeaDrill (NYSE:SDRL) went up 3.81%: ChemoCentryx (NASDAQ:CCXI), Verastem (NASDAQ:VSTM), Sophiris Bio, Inc ...KC RegisterOn 9 May, Verastem, Inc. (NASDAQ:VSTM) reported that, Net loss for the first quarter ended March 31, 2016 (2016 Quarter) was $8.3 million, or $0.22 per share, as compared to a net loss of $15.2 million, or $0.46 per share, for the first quarter ended ...and more »
05/25/16 06:29 PMVerastem Inc. (VSTM) Jumps 9.79% on May 24 - Equities.com - Verastem Inc. (VSTM) Jumps 9.79% on May 24Equities.comVerastem Inc. (VSTM) was among the biggest gainers on the Russell 2000 for Tuesday May 24 as the stock popped 9.79% to $1.57, representing a gain of $0.14 per share. Some 1.22 million shares traded hands on 2,140 trades, compared with an average ...and more »
05/24/16 11:46 PMEarnings Review and Stock Rundown for Verastem, Inc. (NASDAQ:VSTM) - Wall Street Hints and News - Earnings Review and Stock Rundown for Verastem, Inc. (NASDAQ:VSTM)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Verastem, Inc. (NASDAQ:VSTM) to post ...Hold Calls Count For Verastem, Inc. (NASDAQ:VSTM) At 4Equities Focusall 381 news articles »
05/17/16 06:20 PMShare Recap and Earnings Focus on Verastem, Inc. (NASDAQ:VSTM) - Wall Street Hints and News - Share Recap and Earnings Focus on Verastem, Inc. (NASDAQ:VSTM)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Verastem, Inc.and more »
05/16/16 12:03 PMVERASTEM, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/11/16 06:57 PMConsensus Rating Review for Verastem, Inc. (NASDAQ:VSTM) - B.O.D.Y Confidential - Consensus Rating Review for Verastem, Inc. (NASDAQ:VSTM)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 2.13 on shares of Verastem, Inc. (NASDAQ:VSTM). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell, or ...and more »
05/11/16 06:57 PMResearch Analysts Issue Forecasts for Verastem Inc's Q3 2016 Earnings (VSTM) - Washington News Wire - Washington News WireResearch Analysts Issue Forecasts for Verastem Inc's Q3 2016 Earnings (VSTM)Washington News WireVerastem logo Verastem Inc (NASDAQ:VSTM) – Equities researchers at Jefferies Group issued their Q3 2016 EPS estimates for Verastem in a note issued to investors on Monday, Zacks Investment Research reports. Jefferies Group analyst B. Amin expects ...
05/11/16 06:57 PMAnalysts Offer Predictions for Verastem Inc's FY2018 Earnings (VSTM) - Washington News Wire - Washington News WireAnalysts Offer Predictions for Verastem Inc's FY2018 Earnings (VSTM)Washington News WireVerastem logo Verastem Inc (NASDAQ:VSTM) – Equities research analysts at Roth Capital issued their FY2018 earnings per share (EPS) estimates for shares of Verastem in a report issued on Monday, Zacks Investment Research reports. Roth Capital ...Verastem Inc (VSTM) Lowered to Hold at Zacks Investment ResearchWeb Breaking Newsall 3 news articles »
05/10/16 06:52 PMSizzling HC Stocks Update: Galena Biopharma Inc (GALE), Verastem Inc (VSTM), Omeros Corporation (OMER) - share market updates (press release) - share market updates (press release)Sizzling HC Stocks Update: Galena Biopharma Inc (GALE), Verastem Inc (VSTM), Omeros Corporation (OMER)share market updates (press release)Shares of Galena Biopharma Inc (NASDAQ:GALE) ended Monday session in green amid volatile trading. The shares closed up +0.07 points or 5.60% at $1.32 with 1.05 million shares getting traded. Post opening the session at $1.23, the shares hit an ...and more »
05/09/16 04:24 PMVerastem reports 1Q loss -
05/09/16 04:23 PMVERASTEM, INC. Files SEC form 10-Q, Quarterly Report -
05/09/16 03:28 PMVerastem Reports First Quarter 2016 Financial Results - [at noodls] - BOSTON--(BUSINESS WIRE)--May 9, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the first quarter ended March 31, ...
05/08/16 07:08 PMVerastem, Inc. (VSTM) Broker Price Targets For The Coming Week - Share Trading News - Verastem, Inc. (VSTM) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Verastem, Inc. (VSTM). The latest reports which are currently in issue on Sunday 8th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts ...How Analysts Feel About Verastem Inc (NASDAQ:VSTM)?Franklin Independentall 2 news articles »
05/05/16 07:08 PMVerastem, Inc. (VSTM) Updated Broker Price Targets - Share Trading News - Verastem, Inc. (VSTM) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Verastem, Inc. (VSTM). The latest reports which are currently in issue on Thursday 5th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...Verastem Inc (VSTM) Stock Rating Upgraded by Zacks Investment ResearchWeb Breaking Newsall 2 news articles »
05/04/16 05:06 AMAverage Analyst Rating for Verastem, Inc. (NASDAQ:VSTM) - B.O.D.Y Confidential - Average Analyst Rating for Verastem, Inc. (NASDAQ:VSTM)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 2.13 on Verastem, Inc. (NASDAQ:VSTM) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/03/16 06:47 PMVerastem Inc. (VSTM) Drops 5.45% on May 02 - Equities.com - Verastem Inc. (VSTM) Drops 5.45% on May 02Equities.comVerastem Inc. (VSTM) was one of the Russell 2000's biggest losers for Monday May 02 as the stock slid 5.45% to $1.56, a loss of $-0.09 per share. Starting at an opening price of $1.65 a share, the stock traded between $1.51 and $1.67 over the course of ...and more »
05/03/16 08:40 AMVerastem Announces the Presentation of Clinical Data at iMig 2016 - [at noodls] - - VS-6063 generally well tolerated; early signs of tumor reduction observed - - Results from Cohort 2 continue encouraging observations from Cohort 1 for single-agent VS-6063 in chemotherapy-naïve patients ...
04/30/16 06:44 PMVerastem, Inc. (NASDAQ:VSTM) ABR of 2.13 - RealistInvestor.com - Verastem, Inc. (NASDAQ:VSTM) ABR of 2.13RealistInvestor.comAnalysts have a buy call on Verastem, Inc. (NASDAQ:VSTM) stock. As of 2016-04-29, the stock has an ABR of 2.13. This rating comes on a scale of 1-5, where one makes a strong buy call, and 3 indicates Strong Sell. This ABR computation is done on basis ...and more »
04/29/16 06:55 PMTraders Targeted Movers: Verastem, Inc. (NASDAQ:VSTM) , Chimerix, Inc. (NASDAQ:CMRX) - Street Updates - Web Breaking NewsTraders Targeted Movers: Verastem, Inc. (NASDAQ:VSTM) , Chimerix, Inc. (NASDAQ:CMRX)Street UpdatesOn4/28/2016, shares of Verastem, Inc. (NASDAQ:VSTM) fell +0.00% in trading session and finally closed at $1.68. The company most recent volume stood at 1.51 million shares as compared to its average volume of 499.73 thousand shares. Over the one ...Verastem Inc (NASDAQ:VSTM) Receives Consensus Rating of "Hold" from BrokeragesWeb Breaking NewsVerastem Incorporated (NASDAQ:VSTM) Shorted Shares Increased 15.32% After Market SellingFranklin Independentall 3 news articles »
04/27/16 07:02 PMVerastem, Inc. (NASDAQ:VSTM) Share Rating Recap - B.O.D.Y Confidential - Verastem, Inc. (NASDAQ:VSTM) Share Rating RecapB.O.D.Y ConfidentialShares of Verastem, Inc. (NASDAQ:VSTM) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from financial ...and more »
04/27/16 07:02 PMBroker Changes For Verastem, Inc. (VSTM) - Risers & Fallers - Broker Changes For Verastem, Inc. (VSTM)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Verastem, Inc. (VSTM). The latest broker reports which are currently outstanding on Wednesday 27th of April state 0 analysts have a rating of “strong buy”, 0 analysts “buy ...
04/27/16 07:02 PMVerastem Inc. (VSTM) is Trading Lower on Unusual Volume for April 26 - Equities.com - Verastem Inc. (VSTM) is Trading Lower on Unusual Volume for April 26Equities.comVerastem Inc. (VSTM) experienced unusually high volume on Apr. 26, as the stock lost 8.6% to a closing price of $1.70. The stock saw 906,438 shares trade hands over the course of the day on 3,027 trades. Given that the stock's average daily volume over ...and more »
04/26/16 06:56 PMVerastem Inc. (VSTM) Jumps 17.72% on April 25 - Equities.com - Verastem Inc. (VSTM) Jumps 17.72% on April 25Equities.comVerastem Inc. (VSTM) was among the biggest gainers on the Russell 2000 for Monday April 25 as the stock popped 17.72% to $1.86, representing a gain of $0.28 per share. Some 1.77 million shares traded hands on 4,566 trades, compared with an average ...and more »
04/25/16 08:54 PMEarnings Expectation Watch List: Verastem Inc (NASDAQ:VSTM) - News Oracle - News OracleEarnings Expectation Watch List: Verastem Inc (NASDAQ:VSTM)News OracleLast Trade: The Company rose 3.27% and finished at $1.58. The daily volume was measured at 671,847.00 shares. The 52-week high of the share price is $10.20 and the 52-week low is $1.05. The company has a market cap of $62.82 million. Its latest ...
04/25/16 08:54 PMFloating Price Update: Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) , Verastem, Inc. (NASDAQ:VSTM) - Street Updates - Floating Price Update: Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) , Verastem, Inc. (NASDAQ:VSTM)Street UpdatesVerastem, Inc. (NASDAQ:VSTM) after beginning at $1.55, closed at $1.58 by building up +3.27% in recent trading session. Most recent session's volume of 671.85 thousand shares greater than its average volume of 462.55 thousand shares. The company has ...and more »
04/22/16 07:13 PMHealthcare Sector Update: Verastem Inc (VSTM), Endologix, Inc. (ELGX) - News Oracle - News OracleHealthcare Sector Update: Verastem Inc (VSTM), Endologix, Inc. (ELGX)News OracleVerastem Inc (NASDAQ:VSTM) surged 4.08% yesterday and closed at $1.53. The company's market capitalization is at $56.22 Million with an average trading volume of 293,973.00. The total number of Outstanding Shares Held by the company are 36.99 ...Broker Roundup For Verastem, Inc. (VSTM)Share Trading NewsHow Many Verastem Inc (NASDAQ:VSTM)'s Analysts Are Bearish?CCH Daily NewsMorning Alert: China Distance Education Holdings Limited (NYSE:DL), Sirius XM Holdings Inc. (NASDAQ:SIRI ...Stock Transcriptall 4 news articles »
04/21/16 07:10 PMVerastem, Inc. (NASDAQ:VSTM) Share Rating Recap - The Post - Verastem, Inc. (NASDAQ:VSTM) Share Rating RecapThe PostShares of Verastem, Inc. (NASDAQ:VSTM) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from financial ...and more »
04/21/16 07:10 PMBroker Roundup For Verastem, Inc. (VSTM) - Share Trading News - Broker Roundup For Verastem, Inc. (VSTM)Share Trading News07/11/2014 – Verastem, Inc. had its “buy” rating reiterated by analysts at Deutsche Bank. They now have a USD 14 price target on the stock. The share price of Verastem, Inc. (VSTM) was up +2.04% during the last trading session, with a day high of 1.54.
04/19/16 12:53 AMDicerna Pharmaceuticals : Announces Appointment of John “Jack” Green as Chief Financial Officer - Prior to joining Dicerna as CFO, he served as CFO of Verastem, Inc. (VSTM). Previously, he served for more than 15 years as CFO of GTC Biotherapeutics (formerly Genzyme Transgenics), a publicly-traded biotechnology company spun out of Genzyme as a stand ...
04/18/16 07:21 PMVerastem (VSTM) Appoints Gregory I. Berk, MD as CMO - StreetInsider.com - Verastem (VSTM) Appoints Gregory I. Berk, MD as CMOStreetInsider.comVerastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced the appointment of Gregory I. Berk, MD as Chief Medical Officer. Dr. Berk will be responsible for leading the Company's global clinical ...and more »
04/18/16 04:38 PMVerastem Names Gregory I. Berk, MD as Chief Medical Officer - [at noodls] - - Announces Additional Key Executive Management Appointments and Changes - BOSTON--(BUSINESS WIRE)--Apr. 18, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, ...
04/18/16 04:31 PMVERASTEM, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits -
04/18/16 04:21 PM5:21 pm Verastem names Gregory Berk, MD as Chief Medical Officer -
04/18/16 06:11 AMVerastem Co-Founder, Dr. Robert Weinberg, Recognized with Two Prestigious Cancer Research Awards - [at noodls] - - Salk Institute Medal of Excellence and American Association of Cancer Research Lifetime Achievement Award for Cancer Research - BOSTON--(BUSINESS WIRE)--Apr. 18, 2016-- Verastem, Inc. (NASDAQ:VSTM), ...
04/15/16 07:05 PMVerastem, Inc. (NASDAQ:VSTM): Quick Look at Earnings - News Tribune - Verastem, Inc. (NASDAQ:VSTM): Quick Look at EarningsNews TribuneWhen Verastem, Inc. (NASDAQ:VSTM) issues their next quarterly report on or near 2016-05-09, Wall Street analysts are predicting they will report earnings per share of $-0.32. This consensus EPS number is provided by Zacks Research, which might differ ...and more »
04/15/16 07:05 PMVerastem, Inc. (NASDAQ:VSTM) Analyst Recommendation Outlook - Clinton Financial - Verastem, Inc. (NASDAQ:VSTM) Analyst Recommendation OutlookClinton FinancialThere are 5 analysts providing ratings for Verastem, Inc. (NASDAQ:VSTM). 3 have given the stock a “Strong Buy”, 1 rate it a “Buy”, 4 are rating the stock a Hold, and 0 are recommending “Sell”. Every recommendation can be mapped to an integer based ...and more »
04/15/16 12:25 AMVerastem Incorporated (NASDAQ:VSTM) Short Interest Decreased By 3.1% - Clinton Financial - Clinton FinancialVerastem Incorporated (NASDAQ:VSTM) Short Interest Decreased By 3.1%Clinton FinancialThe short interest to Verastem Incorporated's float is 4.64%. The stock increased 2.72% or $0.04 during the last trading session, hitting $1.51. About 391,778 shares traded hands. Verastem Inc (NASDAQ:VSTM) has declined 76.37% since September 8, 2015 ...and more »
04/13/16 07:00 PMVerastem, Inc. (NASDAQ:VSTM)'s 52-Week Price Target At $2.83 - Investor Newswire - Verastem, Inc. (NASDAQ:VSTM)'s 52-Week Price Target At $2.83Investor NewswireThomson Reuters completed its industry survey and following that it has given a 52-week price estimate of $2.83 to Verastem, Inc. (NASDAQ:VSTM) stock. It is the average of the price estimates given by the brokerages during First Call survey. Last year ...and more »
04/13/16 07:00 PMVerastem, Inc. (NASDAQ:VSTM) 50-Day Moving Average At $1.39 - Investor Newswire - Verastem, Inc. (NASDAQ:VSTM) 50-Day Moving Average At $1.39Investor NewswireThe technical analysis of Verastem, Inc. (NASDAQ:VSTM) stock highlights that it is trading $-0.01 points away -0.49% from its 50-day MA of $1.39. Further it is trading $-0.28 or -16.70% away its 200-day MA of $1.66. After considering the last trading ...and more »
03/30/16 03:21 PMVerastem Announces Presentation of Scientific Data Supporting FAK Inhibition in Combination with Immunotherapy at the Keystone Symposium on Cancer Pathophysiology - [at noodls] - BOSTON--(BUSINESS WIRE)--Mar. 30, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the oral presentation of preclinical data by the Company's ...
03/22/16 03:19 PMVerastem Announces Oral Presentation of Data Supporting the Preferential Targeting of Ovarian Cancer Stem Cells at the Society of Gynecologic Oncology’s 2016 Annual Meeting on Women’s Cancer - [at noodls] - BOSTON--(BUSINESS WIRE)--Mar. 22, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of scientific data at the Society of ...
03/16/16 03:41 PMVerastem to Present Data Supporting FAK/PYK2 Inhibition at the 2016 American Academy of Cancer Research Annual Meeting - [Business Wire] - Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced the presentation of scientific data at the 2016 American Association of Cancer Research Annual Meeting being held April 16-20, 2016 in New Orleans, LA.
03/10/16 12:04 PMVERASTEM, INC. Financials -
About Verastem

Verastem logoVerastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Company's VS-6063 (defactinib) and VS 4718 are orally available small molecule compounds designed to inhibit FAK signaling. The Company's VS-5584 is an orally available small molecule that inhibits both mTORC1/2 and PI3K signaling. The Company is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: VSTM
  • CUSIP: 92337C10
Key Metrics:
  • Previous Close: $1.31
  • 50 Day Moving Average: $1.44
  • 200 Day Moving Average: $1.47
  • P/E Ratio: N/A
  • P/E Growth: -0.68
  • Market Cap: $48.46M
  • Current Quarter EPS Consensus Estimate: $-1.09 EPS
Additional Links:
Verastem (NASDAQ:VSTM) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha